PRESS RELEASE

Q3 2025 — Press release

Q3 2025PDF · 14 pages221 KB
- 1 -
News Release
____________________________________________________________________________
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial
Results
- 	Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024;
Excluding the Impact of Foreign Exchange, Sales Grew 3%
o 	KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 8%
o 	WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and
Excluding the Impact of Foreign Exchange
o 	CAPVAXIVE Sales Were $244 Million
o 	GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7 Billion; Excluding the
Impact of Foreign Exchange, Sales Declined 25%
o 	Animal Health Sales Grew 9% to $1.6 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 7%
- 	GAAP EPS Was $2.32; Non-GAAP EPS Was $2.58; GAAP and Non-GAAP EPS Include
a Charge of $0.10 per Share for Milestone Payment to LaNova for Technology Transfer
for MK-2010
- 	Received FDA Approval of KEYTRUDA QLEX Injection for Subcutaneous Use Across
All Solid Tumor Indications for KEYTRUDA
- 	Presented New Research Across More Than 20 Types of Cancer and Multiple
Treatment Settings at ESMO Congress 2025, Including Positive Survival Data From
KEYNOTE-905 and KEYNOTE-B96
- 	Announced Positive Topline Results From Third Phase 3 CORALreef Lipids Trial of
Enlicitide Decanoate for Treatment of Adults With Hypercholesterolemia
- 	Completed Acquisition of Verona Pharma and Its First-In-Class COPD Maintenance
Treatment for Adults, OHTUVAYRE, in October
- 	Full-Year 2025 Financial Outlook
o 	Now Expects Worldwide Sales To Be Between $64.5 Billion and $65.0 Billion
o 	Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.93
and $8.98
RAHWAY, N.J., Oct. 30, 2025 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as
MSD outside the United States and Canada, today announced financial results for the third
quarter of 2025.
“In the third quarter, we continued to execute on our strategy with important pipeline
advancements, significant approvals and successful new product launches,” said Robert M.
Davis, chairman and chief executive officer. “We’re delivering value to patients and customers
through our innovative portfolio of medicines and vaccines, and we’re securing our future by

-- 1 of 14 --

- 2 -
making important investments in our pipeline – including through compelling, strategic business
development like our completed acquisition of Verona Pharma and expanded U.S.
manufacturing and R&D spending. With each milestone we achieve, my conviction that we’re
well-positioned to drive the next chapter of success for our Company increases.”
Financial Summary
Third Quarter
$ in millions, except EPS amounts 	2025 	2024 	Change
Change Ex-
Exchange
Sales 	$17,276 	$16,657 	4% 	3%
GAAP net income1 	5,785 	3,157 	83% 	84%
Non-GAAP net income that excludes certain items1,2* 	6,448 	3,985 	62% 	62%
GAAP EPS 	2.32 	1.24 	87% 	88%
Non-GAAP EPS that excludes certain items2* 	2.58 	1.57 	64% 	65%
*Refer to table on page 7.
For the third quarter of 2025, Generally Accepted Accounting Principles (GAAP)
earnings per share (EPS) assuming dilution was $2.32 and non-GAAP EPS was $2.58. GAAP
and non-GAAP EPS in the third quarter of 2025 include a charge of $0.10 per share for a
milestone payment to LaNova Medicines Ltd. (LaNova, acquired by Sino Biopharmaceutical
Limited) associated with the technology transfer for MK-2010. GAAP and non-GAAP EPS in the
third quarter of 2024 include a net charge of $0.79 per share in the aggregate for the acquisition
of Eyebiotech Limited (EyeBio) and a related development milestone, the acquisition of MK-
1045 from Curon Biopharmaceutical (Curon), as well as a payment received from Daiichi
Sankyo related to the expansion of the existing development and commercialization agreement
to include gocatamig (MK-6070).
Non-GAAP EPS in both periods excludes acquisition- and divestiture-related costs,
costs related to restructuring programs, and income and losses from investments in equity
securities. Non-GAAP EPS in the third quarter of 2025 also excludes tax expense relating to
audit reserve adjustments.
Year-to-date results can be found in the attached tables.
1 Net income attributable to the Company.
2 The Company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of
these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in
addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-
GAAP adjustments, see Table 2a attached to this release.

-- 2 of 14 --

- 3 -
Third-Quarter Sales Performance
The following table reflects sales of the Company’s top products and significant
performance drivers.
Third Quarter
$ in millions 	2025 	2024 	Change
Change Ex-
Exchange 	Commentary
Total Sales 	$17,276 	$16,657 	4% 	3%
Pharmaceutical 	15,611 	14,943 	4% 	3%
Increase primarily driven by growth
in oncology, cardiovascular and
diabetes, partially offset by declines
in vaccines, virology and
immunology.
KEYTRUDA 	8,142 	7,429 	10% 	8%
Growth driven by continued strong
global demand from metastatic
indications, including urothelial,
endometrial and gastric cancers, as
well as robust global uptake in
earlier-stage indications including
triple-negative breast cancer,
cervical cancer, renal cell carcinoma
(RCC) and non-small cell lung
cancer (NSCLC). Sales also
benefitted from timing of wholesaler
purchases in the U.S., partially offset
by other channel movements.
GARDASIL/GARDASIL 9 	1,749 	2,306 	-24% 	-25%
Decline primarily due to lower
demand in China. Excluding China,
sales declined 2%, or 3% excluding
impact of foreign exchange,
reflecting lower demand in Japan
following a national catch-up
immunization program, partially
offset by higher sales in the U.S. due
to higher net pricing and favorable
public-sector purchasing patterns.
PROQUAD, M-M-R II and
VARIVAX 	684 	703 	-3% 	-3%
Decline primarily due to lower
demand, partially offset by higher net
pricing in the U.S.
JANUVIA/JANUMET 	624 	482 	29% 	29%
Growth driven by higher net pricing
in the U.S., partially offset by lower
demand in China as well as in most
other international markets due to
generic competition.
BRIDION 	439 	420 	5% 	4%
Growth primarily due to higher
demand in the U.S., partially offset
by lower demand in most
international markets due to ongoing
generic competition.
Lynparza* 	379 	337 	12% 	12%
Growth primarily due to higher
demand in the U.S. and certain
international markets.
WINREVAIR 	360 	149 	141% 	141%
Growth largely reflects continued
uptake in the U.S., partially offset by
timing of distributor purchases and
lower net pricing in the U.S. largely
due to Medicare Part D redesign.

-- 3 of 14 --

- 4 -
PREVYMIS 	266 	208 	28% 	25%
Increase primarily due to higher
demand in the U.S. and launch of
new indications in certain
international markets, partially offset
by lower demand in China due to
generic competition.
Lenvima* 	258 	251 	3% 	2%
Increase primarily due to higher
sales in the U.S. reflecting higher
demand, partially offset by lower net
pricing.
CAPVAXIVE 	244 	47 	N/M 	N/M
Represents continued uptake since
third-quarter 2024 launch in the U.S.,
as well as expected seasonal
inventory build.
VAXNEUVANCE 	226 	239 	-6% 	-7%
Decline primarily due to lower
demand in certain international
markets, particularly in Japan due to
competitive pressure, partially offset
by higher demand in certain
European markets.
WELIREG 	196 	139 	42% 	41%
Growth primarily driven by higher
demand in the U.S. and continued
launch uptake in certain European
markets, partially offset by lower net
pricing in the U.S.
LAGEVRIO 	138 	383 	-64% 	-65%
Decline primarily due to lower
demand in the Asia Pacific region,
particularly in Japan, as well as in
the U.S.
SIMPONI 	- 	189 	-100% 	-100%
Marketing rights in former territories
of the Company reverted to Johnson
& Johnson on Oct. 1, 2024.
Animal Health 	1,615 	1,487 	9% 	7%
Growth primarily due to performance
of livestock products.
Livestock 	1,023 	886 	16% 	14%
Growth primarily driven by higher
demand across all species, as well
as timing of sales.
Companion Animal 	592 	601 	-2% 	-3%
Decline primarily due to lower
demand, reflecting a reduction in
veterinary visits and competitive
pressure for parasiticides, partially
offset by higher pricing, improved
supply and new product launches.
Sales of BRAVECTO were $262
million and $266 million in current
and prior-year quarters, respectively,
which represents a decline of 1%, or
3% excluding impact of foreign
exchange.
Other Revenues** 	50 	227 	-78% 	-27%
Decline primarily due to unfavorable
impact of revenue-hedging activities
and lower revenue from third-party
manufacturing arrangements.
*Alliance revenue for this product represents the Company’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
N/M- Not meaningful.

-- 4 of 14 --

- 5 -
In addition, Koselugo alliance revenue was $214 million in the third quarter of 2025
compared with $39 million in the third quarter of 2024. The increase was due to an amendment
to the collaboration agreement with AstraZeneca, which discontinued the provisions whereby
the Company shared revenue and costs with AstraZeneca, and revised the payment structure,
resulting in the Company’s recognition of a $150 million upfront payment and a $50 million
regulatory milestone.
Third-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities 	Non-GAAP2
Third Quarter 2025
Cost of sales 	$3,855 	$621 	$110 	$- 	$3,124
Selling, general and administrative 	2,633 	34 	- 	- 	2,599
Research and development 	4,234 	4 	233 	- 	3,997
Restructuring costs 	47 	- 	47 	- 	-
Other (income) expense, net 	(238) 	- 	- 	(344) 	106
Third Quarter 2024
Cost of sales 	$4,080 	$639 	$192 	$- 	$3,249
Selling, general and administrative 	2,731 	43 	31 	- 	2,657
Research and development 	5,862 	24 	- 	- 	5,838
Restructuring costs 	56 	- 	56 	- 	-
Other (income) expense, net 	(162) 	(27) 	- 	58 	(193)
GAAP Expense, EPS and Related Information
Gross margin was 77.7% for the third quarter of 2025 compared with 75.5% for the third
quarter of 2024. The increase was primarily due to the favorable impact of product mix and
lower restructuring costs, partially offset by higher inventory write-offs and the unfavorable
impact of foreign exchange.
Selling, general and administrative (SG&A) expenses were $2.6 billion in the third
quarter of 2025, a decrease of 4% compared with the third quarter of 2024. The decrease was
primarily due to lower administrative, restructuring and selling costs, partially offset by the
unfavorable impact of foreign exchange.
Research and development (R&D) expenses were $4.2 billion in the third quarter of
2025, a decrease of 28% compared with the third quarter of 2024. The decrease was primarily
due to lower charges for business development activity, including charges of $2.2 billion in the
aggregate related to the acquisitions of EyeBio and MK-1045 in the third quarter of 2024,
3 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well as
amortization of intangible assets related to collaborations and licensing arrangements.

-- 5 of 14 --

- 6 -
compared with a charge of $300 million in the third quarter of 2025 related to a milestone
payment to LaNova for the completion of the technology transfer for MK-2010. Excluding these
charges, R&D expenses increased primarily due to higher restructuring costs and clinical
development spending.
Other (income) expense, net, was $238 million of income in the third quarter of 2025
compared with $162 million of income in the third quarter of 2024. The favorability was primarily
due to net income from investments in equity securities in 2025 compared with net losses from
investments in equity securities in 2024, partially offset by $170 million of income recognized in
2024 related to a payment received from Daiichi Sankyo associated with the expansion of an
existing development and commercialization agreement to include gocatamig (MK-6070).
The effective tax rate was 14.2% for the third quarter of 2025.
GAAP EPS was $2.32 for the third quarter of 2025 compared with $1.24 for the third
quarter of 2024. The increase was primarily driven by a net charge of $0.79 per share in the
aggregate in 2024 for the EyeBio, Curon and Daiichi Sankyo transactions, partially offset by a
charge of $0.10 per share in 2025 related to the LaNova technology transfer milestone
payment.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 81.9% for the third quarter of 2025 compared with 80.5%
for the third quarter of 2024. The increase was primarily due to the favorable impact of product
mix, partially offset by higher inventory write-offs and the unfavorable impact of foreign
exchange.
Non-GAAP SG&A expenses were $2.6 billion in the third quarter of 2025, a decrease of
2% compared with the third quarter of 2024. The decrease was primarily due to lower
administrative and selling costs, partially offset by the unfavorable impact of foreign exchange.
Non-GAAP R&D expenses were $4.0 billion in the third quarter of 2025, a decrease of
32% compared with the third quarter of 2024. The decrease was primarily due to lower charges
for business development activity, including charges of $2.2 billion in the aggregate related to
the acquisitions of EyeBio and MK-1045 in the third quarter of 2024, compared with a charge of
$300 million in the third quarter of 2025 related to a milestone payment to LaNova for the
completion of the technology transfer for MK-2010. Excluding these charges, R&D expenses
increased primarily due to higher clinical development spending.
Non-GAAP other (income) expense, net, was $106 million of expense in the third quarter
of 2025 compared with $193 million of income in the third quarter of 2024. The unfavorability
was primarily due to $170 million of income recognized in 2024 related to a payment received
from Daiichi Sankyo associated with the expansion of an existing development and
commercialization agreement to include gocatamig (MK-6070).

-- 6 of 14 --

- 7 -
The non-GAAP effective tax rate was 13.4% for the third quarter of 2025.
Non-GAAP EPS was $2.58 for the third quarter of 2025 compared with $1.57 for the
third quarter of 2024. The increase was primarily driven by a net charge of $0.79 per share in
the aggregate in 2024 for the EyeBio, Curon and Daiichi Sankyo transactions, partially offset by
a charge of $0.10 per share in 2025 related to the LaNova technology transfer milestone
payment.
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
Third Quarter
$ in millions, except EPS amounts 	2025 	2024
EPS
GAAP EPS 	$2.32 	$1.24
Difference 	0.26 	0.33
Non-GAAP EPS that excludes items listed below2 	$2.58 	$1.57
Net Income
GAAP net income1 	$5,785 	$3,157
Difference 	663 	828
Non-GAAP net income that excludes items listed below1,2 	$6,448 	$3,985
Excluded Items:
Acquisition- and divestiture-related costs3 	$659 	$679
Restructuring costs 	390 	279
(Income) loss from investments in equity securities 	(344) 	58
Decrease to net income before taxes 	705 	1,016
Estimated income tax (benefit) expense4 	(42) 	(188)
Decrease to net income 	$663 	$828
4 Includes the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the
non-GAAP adjustments for both periods presented. Amount in the third quarter of 2025 also includes $86 million of tax expense
relating to audit reserve adjustments.

-- 7 of 14 --

- 8 -
Pipeline and Portfolio Highlights
In the third quarter, the Company continued to demonstrate pipeline progress with the
achievement of key regulatory and clinical milestones.
In oncology, in September 2025, the U.S. Food and Drug Administration (FDA) approved
KEYTRUDA QLEX injection for subcutaneous (SC) administration for use in adults across most
solid tumor indications for KEYTRUDA, based on results from the Phase 3 MK-3475A-D77 trial.
In October 2025, the FDA subsequently approved KEYTRUDA QLEX for the treatment of
certain adult patients with resectable locally advanced head and neck squamous cell carcinoma
(LA-HNSCC), based on results from the Phase 3 KEYNOTE-689 trial. KEYTRUDA QLEX is
now approved for use in adults across all solid tumor indications approved for KEYTRUDA and
is the first and only subcutaneously administered immune checkpoint inhibitor that can be given
by a health care provider in as little as one minute.
In addition, the European Medicines Agency’s Committee for Medicinal Products for
Human Use (CHMP) adopted a positive opinion recommending approval for SC administration
of KEYTRUDA for all adult indications; a final decision is expected in the fourth quarter of 2025.
The European Commission (EC) also approved KEYTRUDA as part of a perioperative regimen
for the treatment of PD-L1+ resectable LA-HNSCC.
At the European Society for Medical Oncology (ESMO) Congress 2025, the Company
announced new research from its broad and differentiated portfolio and pipeline, highlighting
progress in new tumor types and earlier stages of disease. This included positive results from
the Phase 3 KEYNOTE-905 trial (also known as EV-303) in cisplatin-ineligible patients with
muscle-invasive bladder cancer (MIBC), the Phase 3 KEYNOTE-B96 trial in platinum-resistant
recurrent ovarian cancer and the Phase 2/3 REJOICE-Ovarian01 trial in collaboration with
Daiichi Sankyo in certain types of platinum-resistant ovarian cancer, long-term follow-up data
from the Phase 3 KEYNOTE-775 trial in advanced endometrial cancer, as well as long-term
data for KEYTRUDA in both earlier-stage and metastatic NSCLC.
In vaccines and infectious diseases, in August 2025, the Company received two
approvals in Japan: its nine-valent HPV vaccine for use in males ages 9 and older that will be
marketed under the trademark SILGARD 9, and CAPVAXIVE for use in the elderly or adults
who are at an increased risk of pneumococcal disease.
At the European AIDS Clinical Society 2025 conference, the Company also presented
new data from Phase 3 trials evaluating the once-daily, oral, two-drug regimen of
doravirine/islatravir in adults with virologically suppressed HIV-1 infection, which showed
minimal changes in weight and body composition and no clinically meaningful effect on fasting
lipids and the homeostatic model assessment of insulin resistance across both clinical trials.
In cardiovascular disease, the Company announced positive topline results from the
Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate, an
investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor

-- 8 of 14 --

- 9 -
being evaluated for the treatment of adults with hypercholesterolemia. The trial met all primary
and key secondary endpoints. Enlicitide has the potential to be the first approved oral PCSK9
inhibitor.
In addition, the FDA approved an update to the U.S. product label for WINREVAIR,
based on results from the Phase 3 ZENITH trial, expanding the indication to include
components of the clinical worsening events: hospitalization for pulmonary arterial hypertension
(PAH), lung transplantation and death. Further, at the 2025 European Respiratory Society
Congress, the Company presented positive results from the Phase 3 HYPERION trial evaluating
WINREVAIR versus placebo (both in combination with background therapy) in adults recently
diagnosed with PAH (Group 1 pulmonary hypertension) with World Health Organization (WHO)
functional class II or III at intermediate or high risk of disease progression. Results showed that
adding WINREVAIR within the first year after PAH diagnosis significantly reduced the risk of
clinical worsening events compared to placebo.
The Company also completed its acquisition of Verona Pharma plc (Verona Pharma) in
October 2025, strengthening its cardio-pulmonary portfolio with the addition of OHTUVAYRE,
an FDA-approved, first-in-class maintenance treatment for chronic obstructive pulmonary
disease (COPD) in adult patients.
Notable recent news releases on the Company’s pipeline and portfolio are provided in
the table that follows. Visit the News Releases section of the Company’s website to read the
releases.*
Oncology
FDA Approved KEYTRUDA QLEX Injection for SC Use in Adults Across Most Solid Tumor
Indications for KEYTRUDA; Based on Results From Phase 3 MK-3475A-D77 Trial
FDA Granted Breakthrough Therapy Designation for Raludotatug Deruxtecan (R-DXd) for Patients
With CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube
Cancers Previously Treated With Bevacizumab; Based on Results From Phase 1 Trial and
REJOICE-Ovarian01 Phase 2/3 Trial
FDA Granted Breakthrough Therapy Designation for Ifinatamab Deruxtecan (I-DXd) for Patients
With Pretreated Extensive-Stage Small Cell Lung Cancer; Based on Results From Phase 2
IDeate-Lung01 Trial
FDA Granted Priority Review for KEYTRUDA and KEYTRUDA QLEX, Each in Combination With
Padcev, for Certain Patients With MIBC; FDA Set Prescription Drug User Fee Act (PDUFA) Date
of April 7, 2026
EC Approved KEYTRUDA as Part of a Treatment Regimen for Adults With Resectable LA-
HNSCC Expressing PD-L1 (CPS≥1); Based on Results From Phase 3 KEYNOTE-689 Trial
EU CHMP Adopted Two Positive Opinions for KEYTRUDA, for SC Administration and for New
Indication for Earlier-Stage Head and Neck Cancer; Latter Based on Results From Phase 3
KEYNOTE-689 Trial
KEYTRUDA Plus Padcev Reduced Risk of Event-Free Survival Events by 60% and Risk of Death
by 50% for Certain Patients With MIBC When Given Before and After Surgery; Based on Results
From Phase 3 KEYNOTE-905 Trial
KEYTRUDA Plus Chemotherapy, With or Without Bevacizumab, Reduced Risk of Disease
Progression or Death Versus Chemotherapy, With or Without Bevacizumab, in Certain Patients
With Platinum-Resistant Recurrent Ovarian Cancer; Based on Results From Phase 3 KEYNOTE-
B96 Trial; FDA Set PDUFA Date of Feb. 20, 2026
Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival in All Comers
Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

-- 9 of 14 --

- 10 -
R-DXd Demonstrated Clinically Meaningful Response Rates in Patients With Recurrent Platinum-
Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-
Ovarian01 Phase 2/3 Trial
KEYTRUDA Demonstrated Long-Term Survival Benefit in Certain Patients With Earlier or
Advanced Stages of NSCLC; Based on Exploratory Five-Year Analyses of Phase 3 KEYNOTE-
671 Trial, Eight-Year Analyses of Phase 3 KEYNOTE-024 and KEYNOTE-042 Trials, and 10-Year
Analyses of Phase 1b KEYNOTE-001 and Phase 2/3 KEYNOTE-010 Trials
KEYTRUDA Plus Lenvima Demonstrated Durable Five-Year Survival Benefit Versus
Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-
Based Regimen; Based on Results From Phase 3 KEYNOTE-775 Trial
WELIREG Plus Lenvima Met Primary Endpoint of Progression-Free Survival in Certain Previously
Treated Patients With Advanced RCC; Based on Results From Phase 3 LITESPARK-011 Trial
KEYTRUDA Plus WELIREG Met Primary Endpoint of Disease-Free Survival in Certain Patients
With Clear Cell RCC Following Nephrectomy; Based on Results From Phase 3 LITESPARK-022
Trial
I-DXd Demonstrated Clinically Meaningful Response Rates in Patients With Extensive-Stage
Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan (HER3-DXd) Initiated in Patients
With Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Previously Treated
With Endocrine Therapy
Vaccines and
Infectious Diseases
CAPVAXIVE Demonstrated Positive Immune Responses in Children and Adolescents at
Increased Risk of Pneumococcal Disease; Based on Results From Phase 3 STRIDE-13 Trial
The Company Announced New Data From Phase 3 Trials Evaluating the Investigational, Once-
Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir in Adults With Suppressed HIV-1 Infection;
Based on Results From Phase 3 MK-8591A-051 and MK-8591A-052 Trials
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of
Pneumococcal Serotypes Covered by CAPVAXIVE in U.S. Adults
Cardiovascular
FDA Approved Updated Indication for WINREVAIR in Adults With PAH Based on Phase 3
ZENITH Study
WINREVAIR Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in
Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in
Adults With Hypercholesterolemia in Pivotal Phase 3 CORALreef Lipids Study
Immunology The Company Expanded Tulisokibart Clinical Development Program With Initiation of Phase 2b
Trials in Three Additional Immune-Mediated Inflammatory Diseases
*References to the Company’s name in the above news release titles have been modified for the purpose of this announcement.
Manufacturing and R&D Investment
The Company continued to make long-term investments in its U.S. manufacturing and
R&D capabilities and broke ground on a new $3 billion Center of Excellence for Pharmaceutical
Manufacturing at its Elkton, Virginia site. The 400,000-square-foot facility will include both active
pharmaceutical ingredient and drug product investment to support small molecule
manufacturing and testing, creating more than 500 full-time jobs. This investment is part of the
Company’s commitment to dedicate more than $70 billion beginning in 2025 to expand
domestic manufacturing and R&D — not including any future business development in R&D —
to drive its long-term growth and strengthen the U.S. as a global leader in biopharmaceutical
innovation.
Upcoming Investor Event
The Company also plans to present new data from its innovative cardiovascular pipeline
and portfolio at the American Heart Association (AHA) Scientific Sessions 2025 from Nov. 7-10.
The Company will host an Investor Event to coincide with the AHA Scientific Sessions 2025 on
Sunday, Nov. 9 at 6 p.m. CT. The event will take place in New Orleans and will be accessible
via live audio webcast at this weblink.

-- 10 of 14 --

- 11 -
Sustainability Highlights
The Company’s 2024/2025 Purpose for Progress Impact Report provided a
comprehensive view of how it is pursuing innovative science for the health of people and
animals and ensuring its efforts drive significant and sustainable value. The report noted that the
Company’s medicines and vaccines reached more than 450 million people around the world in
2024.
Full-Year 2025 Financial Outlook
The following table summarizes the Company’s full-year financial outlook.
Full Year 2025
Updated 	Prior
Sales* 	$64.5 billion to $65.0 billion 	$64.3 billion to $65.3 billion
Non-GAAP Gross margin2 	Approximately 82% 	Approximately 82%
Non-GAAP Operating expenses2(a) 	$25.9 billion to $26.4 billion 	$25.6 billion to $26.4 billion
Non-GAAP Other (income) expenses, net2 $400 million to $500 million expense 	$300 million to $400 million expense
Non-GAAP Effective tax rate2 	14.0% to 15.0% 	15.0% to 16.0%
Non-GAAP EPS2(b)(c) $8.93 to $8.98 	$8.87 to $8.97
Share count (assuming dilution) 	Approximately 2.51 billion 	Approximately 2.51 billion
*The Company does not have any non-GAAP adjustments to sales.
(a)Includes one-time R&D charges of $300 million for a milestone payment to LaNova associated with the technology transfer for MK-2010 and
$200 million for an upfront payment for a license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma). Outlook does
not assume any additional significant potential business development transactions.
(b)Includes one-time charges totaling $0.16 per share associated with the payment for the LaNova technology transfer for MK-2010 and the
upfront payment to Hengrui Pharma.
(c)Updated full-year 2025 outlook reflects a benefit of approximately $0.09 per share resulting from an amendment to the collaboration
agreement with AstraZeneca related to Koselugo, and an estimated negative impact of $0.04 per share related to the acquisition of Verona
Pharma.
The Company has not provided a reconciliation of forward-looking non-GAAP gross
margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP
effective tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it
cannot predict with reasonable certainty the amounts necessary for such a reconciliation,
including intangible asset impairment charges, legal settlements, and income and losses from
investments in equity securities either owned directly or through ownership interests in
investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the Company’s future GAAP results.
The Company now expects full-year 2025 sales to be between $64.5 billion and $65.0
billion, including a negative impact of foreign exchange of approximately 0.5% at mid-October
2025 exchange rates.
The Company now expects its full-year non-GAAP effective income tax rate to be
between 14.0% and 15.0%.
The Company now expects its full-year non-GAAP EPS to be between $8.93 and $8.98,
including a negative impact of foreign exchange of approximately $0.15 per share. This revised

-- 11 of 14 --

- 12 -
non-GAAP EPS outlook reflects several items not previously included, such as a benefit from an
amended collaboration agreement with AstraZeneca related to Koselugo, and operational
improvements, including a more favorable estimated tax rate and lower estimated costs related
to the impact of tariffs, partially offset by an estimated negative impact related to the acquisition
of Verona Pharma and an incremental negative impact from foreign exchange. The midpoint of
this revised non-GAAP EPS range reflects a net improvement of $0.04 per share compared to
the midpoint of the Company’s prior outlook.
As previously communicated, the revised estimated full-year 2025 non-GAAP EPS
range reflects the impacts of the one-time charges in connection with a license agreement with
Hengrui Pharma and the completion of the technology transfer with LaNova for MK-2010, which
impact EPS by approximately $0.16 in the aggregate. In 2024, non-GAAP EPS of $7.65 was
negatively impacted by a net charge of $1.28 per share related to certain asset acquisitions,
licensing agreements and collaborations.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
on Thursday, Oct. 30, at 9 a.m. ET via this weblink. A replay of the webcast, along with the
sales and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available on the Company’s website.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Our Company
At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States
and Canada, we are unified around our purpose: We use the power of leading-edge science to
save and improve lives around the world. For more than 130 years, we have brought hope to
humanity through the development of important medicines and vaccines. We aspire to be the
premier research-intensive biopharmaceutical company in the world – and today, we are at the
forefront of research to deliver innovative health solutions that advance the prevention and
treatment of diseases in people and animals. We foster a diverse and inclusive global workforce
and operate responsibly every day to enable a safe, sustainable and healthy future for all
people and communities.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the

-- 12 of 14 --

- 13 -
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the Company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
Company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described in the forward-looking
statements can be found in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2024 and the Company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)
Koselugo (selumetinib)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
OHTUVAYRE (ensifentrine)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

-- 13 of 14 --

- 14 -
SIMPONI (golimumab)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: 	Investor Contacts:
Michael Levey
michael.levey@msd.com
John Cummins
john.cummins2@msd.com
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583

-- 14 of 14 --